Summary
UFT is a compound in which futraful (FT) and uracil are combined at a ratio of 1:4. UFT was given orally at a daily dose of 300–600 mg in a phase II study. Pooled data on a UFT phase II study of 438 evaluable patients, at 104 institutions revealed a response in carcinoma of the stomach (27.7%), pancreas (25.0%), gallbladder and bile duct (25.0%), liver (19.2%), colon and rectum (25.0%), breast (32.0%), and lung (7.0%). The mainly gastrointestinal toxicity resulted in anorexia (24.3%), nausea and vomiting (12.5%), and diarrhea (11.8%). On the other hand, hematological toxicity was rare and mild. To analyze the lifeprolonging effect of the therapy, a cohort study was carried out in 438 cases collected in the UFT phase II study 5 years after the commencement of the therapy. The 50% survival time for 185 patients with gastric cancer was 185 days. The corresponding times in 54 patients with colorectal cancer and 49 with breast cancer were 227 and 505 days, respectively. A historical comparative study of UFT and FT, which was administered in the same institutions for equal evaluation, revealed that UFT had a significantly better effect than FT without more pronounced side effects with the equivalent dose schedule. In conclusion, UFT can be considered a useful agent against cancers over a broad spectrum, especially in gastrointestinal cancer.
Similar content being viewed by others
References
Fujii S, Ikenaka K, Fukushima M, Shirasaka T (1978) Effect of uracil and its derivatives on antitumor activity of 5-fluorouracil and 1-(2-tetrahydrofuryl)-5-fluorouracil. Jpn J Cancer Res (Gann) 69: 763
Fujii S, Kitano S, Ikenaka K, Shirasaka T (1979) Effect of coadministration of uracil or cytosine on the antitumor activity of clinical doses of 1-(2-tetrahydrofuryl)-5-fluorouracil in rodents. Jpn J Cancer Res (Gann) 70: 209
Fujii S, Kitanos S, Ikenaka K, Shirasaka T (1979) Studies on coadministration of uracil or cytosine on antitumor activity of FT-207 or 5-FU derivatives. Jpn J Cancer Chemother 6: 377
Fujii S, Kitano S, Ikenaka K, Fukushima M, Shirasaka T (1979) Coadministration of thymidine or thymine on antitumor activity of FT-207 or 5-fluorouracil. Jpn J Cancer Chemother 6: 1079
Fukui Y, Imabayashi N, Nishi M, Majima K, Yamamura M, Hioki K, Yamamoto M (1980) Clinical study on the enhancement of drug delivery into tumor tissue by using UFT. Jpn J Cancer Chemother 7: 2124
Furue H, Uchino H, Orita K, Kimura T, Goto Y, Kondo T, Sato S, Takino T, Taguchi T, Nakao I, Nakajima T, Fujimoto S, Miyazaki T, Miyoshi A, Yachi A, Yoshida K, Ogawa N, for SPG Cooperative Study Group of Immunochemotherapy for Gastric Cancer (1985) Clinical evaluation of schizophylan (SPG) in advanced gastric cancer (the second report). A randomized controlled study. Jpn J Cancer Chemother 12: 1272
Ikenaka K, Shirasaka T, Kitano S, Fujii S (1979) Effect of uracil on metabolism of 5-fluorouracil in vitro. Jpn J Cancer Res (Gann) 70: 353
Inoue K, Ogawa M, Inagaki J, Horikoshi N, Ikeda K, Nakada H, Usui N, Asachi K, Tada A, Yamazaki H (1984) A randomized trial and adriamycin, cyclophosphamide, ftorafur (ACF) and adriamycin, cyclophosphamide, ftorafur, methotrexate (ACFM) in patients with advanced breast cancer. Jpn J Cancer Chemother 11: 1832
Inuyama Y, Fujii M, Mashino S, Tanaka J, Takaoka T, Kohno N (1983) Clinical effect of UFT therapy for head and neck cancer. Jpn J Cancer Chemother 10: 90
Jato J, Windheuser JJ (1973) 5-Fluorouracil and derivatives in cancer chemotherapy III. J Pharm Sci 62: 1975
Kimura K, Suga S, Shimaji T, Kitamura M, Kubo K, Suzuoki Y, Isobe K (1980) Clinical basis of chemotherapy for gastric cancer with uracil and 1-(2′-tetrahydrofuryl)-5-fluorouracil. Gastroenterol Jpn 15: 324
Kirkwood JM, Ensminger W, Rosowsky A (1980) Comparison of pharmacokinetics of 5-fluorouracil and 5-fluorouracil with concurrent thymidine infusions in phase I trial. Cancer Res 40: 107
Kunitomo K, Kuwashima T, Korematsu H, Tamura T, Yoshikawa H, Toyosaki M, Komi N (1982) Clinical trial of UFT against recurrent or advanced carcinomas. Jpn J Cancer Chemother 9: 72
Kurihara M, Nakajima T (1981) Chemotherapy of stomach cancer. Shinko-igaku, Tokyo
Majima H (1980) Phase I and preliminary phase II study of co-administration of uracil and FT-207 (UFT therapy). Jpn J Cancer Chemother 7: 1383
Mukherjee KL, Heidelberger C (1960) Studies on fluroinated pyrimidines. J Biol Chem 235: 433
Murakami M, Ota K et al. for Cooperative Study Group of UFT Therapy in Chubu District (1980) Clinical results of UFT therapy for malignant tumors under cooperative study (phase II study). Jpn J Cancer Chemother 7: 1579
Nakajima O, Ihara K, Isoda T, Matsumoto A, Komoda M, Imamura Y, Koyama Y, Kimura T (1980) Phase I and II studies on a mixture of 1-(2-tetrahydrofuryl)-5-fluorouracil and uracil (UFT). Jpn J Cancer Chemother 7: 1558
Nakano Y, et al. for Osaka Cancer Chemotherapy Cooperative Study Group (1980) Clinical Phase II Study of UFT by Cooperative Study Group. Jpn J Cancer Chemother 7: 1569
Nishioka K, Nomura K, Hashimoto S, Matsumoto M, Yunoki K, Tomomatsu H, Shimogawara H, Ichiki T, Furusho H, Takagi S (1981) Clinical effect of UFT on the advanced cancer with special reference to lung cancer. Jpn J Cancer Chemother 8: 294
Rich MA, Bolaffi JL, Knoll JE (1958) Growth inhibition of a human tumor cell strain by 5-fluorouracil, 5-fluorouridine, and 5-fluoro-2′-deoxyuridine reversal studies. Cancer Res 18: 730
Scheiner JM, Kostelak E, Duschinsky R (1957) 5-Fluoropyrimidines as growth inhibitors of microorganisms. Proc Am Assoc Cancer Res 16: 242
Schumacher HJ, Wilson JG, Jordan RJ (1969) Potentiation of the teratogenic effects of 5-fluorouracil by natural pyrimidines. Teratology 2: 99
Shirakawa S, Uehara N, Kita K, Nasu K (1981) Clinical trial on the effect of UFT. Jpn J Cancer Chemother 8: 101
Taguchi T (1984) UFT. Jpn J Cancer Chemother 11: 1692
Taguchi T, Nakano Y, Jikuya K, Fujii S, Ikenaka K, Fukushima M, Shirasaka T (1978) Effect of uracil on the antitumor activity of futraful. Jpn J Cancer Chemother 5: 1161
Taguchi T, Nakano Y, Fujii S, Shirasaka T (1978) determination of 5-fluorouracil levels in tumors, blood, and other tissues. Jpn J Cancer Chemother 5: 1167
Taguchi T, Furue H, Koyama Y, Saito T, Ito I, Majima H, Kimura K, Ota K, Hoshino A, Yamamoto M, Hattori T, Kusumoto G Inokuchi K (1980) Phase I study of UFT (uracil plus futraful preparation). Jpn J Cancer Chemother 7: 966
Taguchi T, Furue H, Kimura T, Kondo T, Hattori T, Itoh I, Ogawa N (1985) End-point results of phase III study of lentinan. Jpn J Cancer Chemother 12: 366
Takino T, Misawa S (1980) Clinical studies on the chemotherapy of advanced cancer with UFT (uracil plus futraful preparation). Jpn J Cancer Chemother 7: 1804
Tamura Y, Okino M, Hongo H, Nakayasu K, Nishikata F, Tokunaga M, Hosoba S, Itoh T, Niimoto M, Hattori T (1981) Phase II study of UFT by collaborative study. Jpn J Cancer Chemother 8: 302
Terasawa T, Koyama H (1986) Breast cancer. Antibiot Chemother 2: 515
Tominaga T, Kaneko H, Ito I (1980) Clinical trial of UFT against advanced cancer. Jpn J Cancer Chemother 7: 2119
Tosen T, Ando K, Ochiai M, Kasajima M, Mori S, Kubochi K (1981) Clinical trial on the effect of UFT. Jpn J Cancer Chemother 8: 715
Watanabe H, Yamamoto S, Naito T, for Tokyo Cancer Chemotherapy Cooperative Study Group (1980) Clinical results of oral UFT therapy under cooperative study. Jpn J Cancer Chemother 7: 1588
Yakeishi Y, Yoshida H, Yokota H, Inui K, Sugama S (1981) Clinical trial of UFT (uracil-futraful preparation) against malignant tumors. Jpn J Cancer Chemother 8: 414
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ota, K., Taguchi, T. & Kimura, K. Report on nationwide pooled data and cohort investigation in UFT phase II study. Cancer Chemother. Pharmacol. 22, 333–338 (1988). https://doi.org/10.1007/BF00254241
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00254241